CSIRO, Australia’s national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern.

Most vaccines require refrigeration to remain effective, like Oxford-AstraZeneca which must be kept between 2-8°C and Pfizer which requires specialized cold storage at -70°C.

CSIRO scientists at the Australian Center for Disease Preparedness in Geelong contributed to the study by assessing vaccinated mice sera (blood samples) for efficacy against key coronavirus variants, including the Delta variant currently spreading globally including in Sydney.

Dr. S.S. Vasan, CSIRO’s COVID-19 project leader and co-author, said the Mynvax-vaccinated mice sera show a strong response to all variants of the live virus.

“Our data shows that all formulations of Mynvax tested result in antibodies capable of consistent and effective neutralization of the Alpha, Beta, Gamma and Delta SARS-CoV-2 variants of concern,” Dr. Vasan said.

CSIRO’s evaluation of the different Mynvax formulations will support selection of the most suitable candidate for planned human clinical trials in India later this year.

News

RNA Recycling Extends Lifespan

Summary: Researchers discovered a biological “trash disposal” mechanism that directly controls how fast we age. While circular RNA has long been known to accumulate in cells as we get older, this study proves for the [...]

Our books now available worldwide!

Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]